Loading
A phase 1/2 trial of Osimertinib, Pembrolizumab, Nivolumab and PM8002 in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06618287 by Bristol-Myers Squibb, with 416 participants planned, started 2025-02-04 and due to reach its primary completion in 2031-02-26. Interventions recorded: BMS-986507, Osimertinib, Pembrolizumab, Nivolumab and Pumitamig.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, Bristol Myers Squibb, Nivolumab and the tag pipeline.
Shares PM8002, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/